Navigation Links
Life Technologies Signs License and Collaborative Stem Cell Research Agreement with Harvard University
Date:3/4/2013

CARLSBAD, Calif., March 4, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) announced today that it has signed a collaborative research agreement and related license with Harvard University under which it has acquired exclusive rights to develop a panel of characterization assays designed to rapidly evaluate human pluripotent stem (hPS) cells for their utility in a variety of discovery and translational research applications. The license expands Life's growing portfolio of stem cell research products and deepens its commitment to customers in the field.

The panel, which will be offered on the company's market-leading semiconductor sequencing and PCR-based genetic analysis platforms, will help overcome major hurdles that impede stem cell technology from moving into the clinic. Current methods for evaluating pluripotency – the potential for induced pluripotent stem (iPS) cells to differentiate into any cell type – are laborious, costly and can produce ambiguous results.

Standardizing the way researchers characterize iPS cells will allow them to quickly identify the most promising cell lines and avoid wasting time and resources on cells that do not possesses the appropriate characteristics. Such efficiency could accelerate applications ranging from development of "disease-in-a-dish" models from patient-derived cells and drug screening, to the eventual use of pluripotent cells as a renewable source for transplantation medicine.

"As iPS cell research grows in scale and moves closer to the clinic, investigators are increasingly in need of characterization standards that enable them to make informed decisions about the quality of their cells," said Chris Armstrong , Ph.D., General Manager and Vice President of Primary and Stem Cell Systems at Life Technologies. "Our investment in this important work developed at Harvard University supports our sustained commitment to provide our customers with the most innovative tools for the iPS cell workflow."

The panel of assays was developed by Alex Meissner , Ph.D., Associate Professor, Department of Stem Cell and Regenerative Biology, Harvard University, and is being further studied and validated in collaboration with Life Technologies. Dr. Meissner is the lead author of a study in the journal Cell (Vol. 144, No. 3, pp. 439-452, Feb. 4, 2011) that identified a range of expression levels among key genes associated with pluripotency. By measuring gene activity in iPS cells against the study's gene expression range, Meissner's lab was able to accurately score cells for their potential to differentiate into particular cell lineages.

"Stem cell research and genomics have rapidly advanced in parallel over the past few years," said Dr. Meissner. "Combining both fields of study is enabling more effective and standardized ways of characterizing pluripotent cells and, therefore, greatly improving efficiency and the application of iPS cells."

Considered a growing segment in the field, the global stem cell characterization market is currently estimated to be $30 million per year, while the overall market for the stem cell research tools is approximately $1 billion, according to BioInformatics LLC.

This announcement marks the third major license agreement in less than a year for Life Technologies' Primary and Stem Cell Systems group. In June 2012, the company retained the non-exclusive global rights from iPS Academia Japan for its iPS cell patent portfolio – enabling Life Technologies to expand its range of products and services. That same month, the company also announced a partnership with Cellular Dynamics International (CDI), the world's largest producer of human cells derived from (iPS) cells, to commercialize a set of new products optimized to consistently develop and grow human iPS cells.

About Life Technologies 
Life Technologies Corporation (NASDAQ:  LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions are secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Mauricio Minotta
760-929-2456
760-805-5266 (mobile)
Mauricio.minotta@lifetech.com


'/>"/>
SOURCE Life Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. UV Flu Technologies Expands Its International Footprint
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
4. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
5. Hologic to Showcase 3D Mammography (Breast Tomosynthesis) and Other Advanced Womens Imaging Technologies at RSNA 2011, the Largest Radiology Show in the World
6. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
7. Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
8. Animal Biotechnology - Technologies, Markets and Companies
9. Gene Therapy - Technologies, Markets and Companies
10. Biomarkers - Technologies, Markets and Companies
11. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... July 20, 2017   KCNQ2 Cure Alliance ... evaluations company, today announced that they have completed ... genetic mutation implicated in KCNQ2 epileptic encephalopathy. They ... a second case involving an additional KCNQ2 genetic ... Alliance and Pairnomix entered into a collaboration to ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... to make clinical trial sites and study participants truly unified. TrialKit, a native ... (FDA 21 CFR Part 11) research studies entirely on mobile devices. With TrialKit, ...
(Date:7/18/2017)... ... July 18, 2017 , ... Sourcing custom glass or quartz parts can be ... capabilities to properly execute your job can take many hours of emails, phone calls ... portal designed to showcase the company’s capabilities and core custom categories, and enables you ...
(Date:7/18/2017)... ... , ... G-CON today announced that it has received Notices ... Applications 14/858,857 and 13/669,785 both entitled Modular, Self-Contained, Mobile Clean Room. The U.S. ... of G-CON’s R&D investments and validate the G-CON platform as a novel way ...
Breaking Biology Technology:
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):